āĻšā§āĻŽZEG âĸ ETR
add
AstraZeneca plc
ā§§ā§Ģā§Ŧ.ā§Šā§ĢâŦ
⧍ āĻāĻžāύā§, ā§§ā§Ļ:ā§Ļā§Ģ:ā§Šā§Ļ PM GMT +ā§§ · EUR · ETR · āĻĄāĻŋāϏāĻā§āϞā§āĻŽāĻžāϰ
āϏā§āĻāĻDE-āĻ āϤāĻžāϞāĻŋāĻāĻžāĻā§āĻā§āϤ āϏāĻŋāĻāĻŋāĻāϰāĻŋāĻāĻŋGB-āĻ āĻšā§āĻĄāĻā§ā§āĻžāϰā§āĻāĻžāϰ
āĻāĻžāϞ āĻļā§āώ āϝ⧠āĻĻāĻžāĻŽā§ āĻāĻŋāϞ
ā§§ā§Ģā§.ā§Žā§ĢâŦ
āϏāĻžāϰāĻž āĻĻāĻŋāύā§āϰ āĻā§āϰā§āĻĄāĻŋāĻā§ā§ āϏā§āĻāĻā§āϰ āĻĻāĻžāĻŽā§āϰ āĻāĻ āĻž āύāĻžāĻŽāĻžāϰ āϰā§āĻā§āĻ
ā§§ā§Ģā§Ŧ.ā§Šā§ĢâŦ - ā§§ā§Ģ⧝.ā§Ģā§ĢâŦ
āϏāĻžāϰāĻž āĻŦāĻāϰā§āϰ āϰā§āĻā§āĻ
ā§§ā§§ā§§.ā§Ļā§ĻâŦ - ā§§ā§Ŧ⧍.ā§Ļā§ĻâŦ
āĻŽāĻžāϰā§āĻā§āĻ āĻā§āϝāĻžāĻĒ
⧍.ā§Žā§āĻā§ USD
āĻāĻĄāĻŧ āĻāϞāĻŋāĻāĻŽ
⧝.ā§Ģā§Ģ āĻšāĻž
P/E āĻ
āύā§āĻĒāĻžāϤ
-
āϞāĻā§āϝāĻžāĻāĻļ āĻĒā§āϰāĻĻāĻžāύ
-
āĻĒā§āϰāĻžāĻāĻŽāĻžāϰāĻŋ āĻāĻā§āϏāĻā§āĻā§āĻ
LON
āĻāĻŦāϰ⧠āϰā§ā§āĻā§
āĻĢāĻžāĻāύāĻžāύā§āϏāĻŋā§āĻžāϞ āĻĒāĻžāϰāĻĢāϰā§āĻŽā§āϝāĻžāύā§āϏ
āĻā§ā§āϰ āϏā§āĻā§āĻāĻŽā§āύā§āĻ
āĻāĻĒāĻžāϰā§āĻāύ
āύā§āĻ āĻāύāĻāĻžāĻŽ
| (USD) | āϏā§āĻĒ ā§¨ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
|---|---|---|
āĻāĻĒāĻžāϰā§āĻāύ | ā§§.ā§Ģ⧍āĻļāĻ¤Â āĻā§ | ā§§ā§§.⧝⧝% |
āĻŦā§āϝāĻŦāϏāĻž āĻāĻžāϞāĻžāύā§āϰ āĻāϰāĻ | ā§Žā§ā§Š.ā§ā§Ļ āĻā§ | ā§Ē.⧍⧝% |
āύā§āĻ āĻāύāĻāĻžāĻŽ | ⧍ā§Ģā§Š.ā§Šā§Ļ āĻā§ | ā§ā§.⧍ā§Ŧ% |
āύā§āĻ āĻĒā§āϰāĻĢāĻŋāĻ āĻŽāĻžāϰā§āĻāĻŋāύ | ā§§ā§Ŧ.ā§Ŧā§ | ā§Ģā§Ž.ā§Šā§§% |
āĻļā§ā§āĻžāϰ āĻĒā§āϰāϤāĻŋ āĻāĻĒāĻžāϰā§āĻāύ | ⧍.ā§Šā§Ž | ā§§ā§¨ā§Ž.ā§Žā§Ģ% |
EBITDA | ā§Ģ⧍⧧.ā§§ā§Ļ āĻā§ | ā§Šā§¨.ā§Žā§Š% |
āĻĒā§āϰāϝā§āĻā§āϝ āĻā§āϝāĻžāĻā§āϏā§āϰ āĻšāĻžāϰ | ⧍⧧.ā§Žā§Ŧ% | â |
āĻŦā§āϝāĻžāϞā§āύā§āϏ āĻļāĻŋāĻ
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
| (USD) | āϏā§āĻĒ ā§¨ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
|---|---|---|
āĻā§āϝāĻžāĻļ āĻ āĻāĻŽ āϏāĻŽā§ā§āϰ āĻŦāĻŋāύāĻŋā§ā§āĻ | ā§Žā§§ā§Ž.⧍ā§Ļ āĻā§ | ā§Ŧā§Ģ.⧝ā§Ŧ% |
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ | ā§§.ā§§ā§ĒāĻā§ | ⧝.ā§Ļ⧝% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§Ŧ.ā§Žā§ĢāĻļāĻ¤Â āĻā§ | ā§Ŧ.ā§Žā§§% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§Ē.ā§Ŧā§ĻāĻļāĻ¤Â āĻā§ | â |
āĻāĻāĻāϏā§āĻā§āϝāĻžāύā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāϰ | ā§§ā§Ģā§Ģ.ā§§ā§Ļ āĻā§ | â |
āĻĒā§āϰāĻžāĻāϏ āĻā§ āĻŦā§āĻ āϰā§āĻļāĻŋāĻ | ā§Ģ.ā§Šā§Š | â |
āϏāĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | ā§Ž.ā§Ļā§% | â |
āĻŽā§āϞāϧāύ āĻĨā§āĻā§ āĻā§ | ā§§ā§§.ā§ā§§% | â |
āĻā§āϝāĻžāĻļ āĻĢā§āϞā§
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ
| (USD) | āϏā§āĻĒ ā§¨ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
|---|---|---|
āύā§āĻ āĻāύāĻāĻžāĻŽ | ⧍ā§Ģā§Š.ā§Šā§Ļ āĻā§ | ā§ā§.⧍ā§Ŧ% |
āĻ
āĻĒāĻžāϰā§āĻļāύ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āϝāĻžāĻļ | ā§Ģā§§ā§Š.ā§Ēā§Ļ āĻā§ | ā§Ģā§§.ā§ā§Ŧ% |
āĻŦāĻŋāύāĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | -⧍ā§Ļā§Ļ.ā§§ā§Ļ āĻā§ | -ā§Šā§¨.ā§§ā§% |
āĻĢāĻžāĻāύā§āϝāĻžāύā§āϏāĻŋāĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | -⧍ā§Ļā§.ā§Šā§Ļ āĻā§ | ā§Ē⧝.ā§Žā§¨% |
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ | ā§§ā§Ļā§Ē.ā§Žā§Ļ āĻā§ | ā§§ā§Ēā§Ŧ.ā§ā§Ē% |
āĻĢā§āϰāĻŋ āĻā§āϝāĻžāĻļ āĻĢā§āϞ⧠| ā§¨ā§Žā§Ļ.ā§Šā§Ģ āĻā§ | ā§Ģā§Ŧ.ā§Ļā§Ē% |
āϏāĻŽā§āĻĒāϰā§āĻā§
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in SÃļdertälje. Wikipedia
āϏāĻŋāĻāĻ
āϏā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§ā§āĻā§
ā§Ŧ āĻāĻĒā§āϰāĻŋ, ⧧⧝⧝⧝
āϏāĻĻāϰ āĻĻāĻĒā§āϤāϰ
āĻā§ā§āĻŦāϏāĻžāĻāĻ
āĻāϰā§āĻŽāĻāĻžāϰā§
⧝ā§Ē,ā§Šā§Ļā§Ļ